Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
First-In-Class Drug’s List Price Is $89,500 Per Year
Apr 30 2022
•
By
Mandy Jackson
The Camzyos REMS requires monthly monitoring in the first three months then once every three months • Source: Alamy
More from New Products
More from Scrip